Discovery of a potent and selective DGAT1 inhibitor with a piperidinyl-oxy-cyclohexanecarboxylic acid moiety

ACS Medicinal Chemistry Letters

Volumn 5, Issue 10, 2014, Pages 1082-1087

  He, Shuwen ^a   Hong, Qingmei ^a   Lai, Zhong ^a   Yang, David X ^a   Ting, Pauline C ^a   Kuethe, Jeffrey T ^a   Cernak, Timothy A ^a   Dykstra, Kevin D ^a   Sperbeck, Donald M ^a   Wu, Zhicai ^a   Yu, Yang ^a   Yang, Ginger X ^a   Jian, Tianying ^a   Liu, Jian ^a   Guiadeen, Deodial ^a   Krikorian, Arto D ^a   Sonatore, Lisa M ^a   Wiltsie, Judyann ^a   Liu, Jinqi ^a   Gorski, Judith N ^a   Chung, Christine C ^a   Gibson, Jack T ^a   Lisnock, Jeanmarie ^a   Xiao, Jianying ^a   Wolff, Michael ^a   Tong, Sharon X ^a   Madeira, Maria ^a   Karanam, Bindhu V ^a   Shen, Dong Ming ^a   Balkovec, James M ^a   Pinto, Shirly ^a   Nargund, Ravi P ^a   Devita, Robert J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

A2A receptor; ACAT1; Ames test; benzimidazole; cyclohexanecarboxylic acid; DGAT1; epimerization; inhibitor; lipid tolerance test; metabolite; skin

Indexed keywords

ACYLTRANSFERASE INHIBITOR; BENZIMIDAZOLE DERIVATIVE; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 1 INHIBITOR; PIPERIDINYL OXY CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOG; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; FOOD INTAKE; HAPLORHINI; HUMAN; HUMAN CELL; INTESTINE; LIVER; LIVER CELL; MOUSE; NONHUMAN; RAT; TISSUE DISTRIBUTION;

EID: 84907937293     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5003426     Document Type: Article

References (34)

1. Birch, A. M.; Buckett, L. K.; Turnbull, A. V. DGAT1 inhibitors as anti-obesity and anti-diabetic agents Curr. Opin. Drug Discovery Dev. 2010, 13, 489-496
2. Cases, S.; Smith, S. J.; Zheng, Y.-W.; Myers, H. M.; Lear, S. R.; Sande, E.; Novak, S.; Collins, C.; Welch, C. B.; Lusis, A. J.; Erickson, S. K.; Farese, R. V., Jr. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13018-13023
3. Cases, S.; Stone, S. J.; Zhou, P.; Yen, E.; Tow, B.; Lardizabal, K. D.; Voelker, T.; Farese, R. V., Jr. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members J. Biol. Chem. 2001, 276, 38870-38876
4. Yen, C. E.; Stone, S. J.; Koliwad, D.; Harris, C.; Farese, R. V., Jr. DGAT enzymes and triacylglycerol biosynthesis J. Lipid Res. 2008, 49, 2283-2301
5. Pramfalk, C.; Eriksson, M.; Parini, P. Cholesteryl esters and ACAT Eur. J. Lipid Sci. Technol. 2012, 114, 624-633
6. Smith, S. J.; Cases, S.; Jensen, D. R.; Chen, H. C.; Sande, E.; Tow, B.; Sanan, D. A.; Raber, J.; Eckel, R. H.; Farese, R. V., Jr. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat Nat. Genet. 2000, 25, 87-90
7. Chen, H. C.; Rao, M.; Sajan, M. P.; Standaerdt, M.; Kanoh, Y.; Miura, A.; Farese, R. V., Jr. Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1 Diabetes 2004, 53, 1445-1451
8. For recent reports of DGAT1 inhibitors, see: Serrano-Wu, M. H.; Kwak, Y.; Coppola, G.; Foster, C.; Gilmore, T.; Gong, Y.; He, G.; Hou, Y.; Kantor, A.; Li, J.; Mergo, W.; Nakajima, K.; Neubert, A.; Radetich, B.; Stroup, B.; Sung, M.; Szklennik, P.; Tichkule, R.; Yang, L.; Yoon, T.; Zhu, Y.; Wareing, J.; Hosagrahara, V.; Jain, M.; Chatelain, R.; Commerford, R.; Dardik, B.; Meyers, D.; Hubbard, B. Discovery of a DGAT1 inhibitor with robust suppression of postprandial triglyceride levels in humans. Abstracts of Papers, 243rd ACS National Meeting & Exposition, San Diego, CA, March 25-29, 2012.
9. Serrano-Wu, M. H.; Coppola, G. M.; Gong, Y.; Neubert, A. D.; Chatelain, R.; Clairmont, K. B.; Commerford, R.; Cosker, T.; Daniels, T.; Hou, Y.; Jain, M.; Juedes, M.; Li, L.; Mullarkey, T.; Rocheford, E.; Sung, M. J.; Tyler, A.; Yang, Q.; Yoon, T.; Hubbard, B. K. Intestinally targeted diacylglycerol acyltransferase 1 (DGAT1) inhibitors robustly suppress postprandial triglycerides ACS Med. Chem. Lett. 2012, 3, 411-415
10. Dow, R. L.; Li, J.-C.; Pence, M. P.; Gibbs, E. M.; LaPerle, J. L.; Litchfield, J.; Piotrowski, D. W.; Munchhof, M. J.; Manion, T. B.; Zavadoski, W. J.; Walker, G. S.; McPherson, R. K.; Tapley, S.; Sugarman, E.; Guzman-Perez, A.; Dasilva-Jardine, P. Discovery of PF-04620110, a potent, selective, and orally bioavailable inhibitor of DGAT-1 ACS Med. Chem. Lett. 2011, 2, 407-412
11. Yeh, V. S.; Beno, D. W.; Brodjian, S.; Brune, M. E.; Cullen, S. C.; Dayton, B. D.; Dhaon, M. K.; Falls, H. D.; Gao, J.; Grihalde, N.; Hajduk, P.; Hansen, T. M.; Judd, A. S.; King, A. J.; Klix, R. C.; Larson, K. J.; Lau, Y. Y.; Marsh, K. C.; Mittelstadt, S. W.; Plata, D.; Rozema, M. J.; Segreti, J. A.; Stoner, E. J.; Voorbach, M. J.; Wang, X.; Xin, X.; Zhao, G.; Collins, C. A.; Cox, B. F.; Reilly, R. M.; Kym, P. R.; Souers, A. J. Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1 J. Med. Chem. 2012, 55, 1751-1757
12. Plowright, A. T.; Barton, P.; Stuart, B.; Alan, M.; Birtles, S.; Buckett, L. K.; Butlin, R. J.; Davies, R. D. M.; Ertan, A.; Gutierrez, P. M.; Kemmitt, P. D.; Leach, A. G.; Svensson, P. H.; Turnbull, A. V.; Waring, M. J. Design and synthesis of a novel series of cyclohexyloxy-pyridyl derivatives as inhibitors of diacylglycerol acyl transferase 1 Med. Chem. Commun. 2013, 4, 151-158
13. Barlind, J. G.; Bauer, U. A.; Birch, A. M.; Birtles, S.; Buckett, L. K.; Butlin, R. J.; Davies, R. D. M.; Eriksson, J. W.; Hammond, C. D.; Hovland, R.; Johannesson, P.; Johansson, M. J.; Kemmitt, P. D.; Lindmark, B. T.; Morentin, P.; Noesk, T. A.; Nordin, A.; ODonnell, C. J.; Petersson, A. U.; Redzic, A.; Turnbull, A. V.; Vinblad, J. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687) J. Med. Chem. 2012, 55, 10610-10629
14. Waring, M. J.; Birch, A. M.; Birtles, S.; Buckett, L. K.; Butlin, R. J.; Campbell, L.; Gutierrez, P. M.; Kemmitt, P. D.; Leach, A. G.; MacFaul, P. A.; ODonnell, C.; Turnbull, A. V. Optimisation of biphenyl acetic acid inhibitors of diacylglycerol acetyl transferase 1: the discovery of AZD2353 Med Chem. Commun. 2013, 4, 159-164
15. Goldberg, F. W.; Birch, A. M.; Leach, A. G.; Groombridge, S. D.; Snelson, W. L.; Gutierrez, P. M.; Hammond, C. D.; Birtles, S.; Buckett, L. K. Discovery and optimization of efficacious neutral 4-amino-6-biphenyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one diacylglycerol acyl transferase-1 (DGAT1) inhibitors Med. Chem. Commun. 2013, 4, 165-174
16. DeVita, R. J.; Pinto, S. Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors J. Med. Chem. 2013, 56, 9820-9825
17. Meyers, C.; Gaudet, D.; Tremblay, K.; Amer, A.; Chen, J.; Aimin, F. The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome J. Clin Lipidol. 2012, 6, 266-267
18. Denison, H.; Nilsson, C.; Kujacic, M.; Löfgren, L.; Karlsson, C.; Knutsson, M.; Eriksson, J. W. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study Diabetes Obes. Metab. 2013, 15, 136-143
19. Denison, H.; Nilsson, C.; Löfgren, L.; Himmelmann, A.; Mårtensson, G.; Knutsson, M.; Al-Shurbaji, A.; Tornqvist, H.; Eriksson, J. W. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial Diabetes Obes. Metab. 2014, 16, 334-343
20. He, S.; Hong, Q.; Lai, Z.; Wu, Z.; Yu, Y.; Kim, D. W.; Ting, P. C.; Kuethe, J. T.; Yang, G. X.; Jian, T.; Liu, J.; Guiadeen, D.; Krikorian, A. D.; Sperbeck, D. M.; Sonatore, L. M.; Wiltsie, J.; Chung, C. C.; Gibson, J. T.; Lisnock, J.; Murphy, B. A.; Gorski, J. N.; Liu, J.; Chen, D.; Chen, X.; Wolff, M.; Tong, S. X.; Madeira, M.; Karanam, B. V.; Shen, D.-M.; Balkovec, J. M.; Pinto, S.; Nargund, R. P.; DeVita, R. J. ACS Med. Chem. Lett. 2013, 4, 773-778
21. 2A receptor as a drug discovery target J. Med. Chem. 2014, 57, 3623-3650
22. For a review on small molecule adenosine receptor agonists and antagonists, see: Müller, C. E.; Jacobson, K. A. Recent developments in adenosine receptor ligands and their potential as novel drugs Biochim. Biophys. Acta 2011, 1808, 1290-1308
23. Chen, H. C.; Smith, S. J.; Tow, B.; Elias, P. M.; Farese, R. V. Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands J. Clin. Invest. 2002, 109, 175-181
24. Subsequently, we carried out a study to evaluate logD as a predictor of skin exposure with subsequent induction of sebaceous gland atrophy: Muise, E. S.; Zhu, Y.; Verras, A.; Karanam, B. V.; Gorski, J.; Weingarth, D.; Lin, H. V.; Hwa, J.; Thompson, J. R.; Hu, G.; Liu, J.; He, S.; DeVita, R. J.; Shen, D.-M.; Pinto, S. Identification and characterization of sebaceous gland atrophy-sparing DGAT1 inhibitors PLoS One 2014, 9, e88908
25. For a report detailing the effort identifying the optimal coupling condition, see: Cernak, T. A.; Manuscript in preparation.
26. For an initial disclosure of the reductive etherification as an efficient strategy to prepare ether compounds, see: Hatakeyama, S.; Mori, H.; Kitano, K.; Yamada, H.; Nishizawa, M. Efficient reductive etherification of carbonyl compounds with alkoxytrimethylsilanes Tetrahedron Lett. 1994, 35, 4367-4370
27. For a report on the application of the reductive etherification strategy for the preparation of 12A, 12B, and related compounds, see: Kuethe, J. T.; Janey, J. M.; Truppo, M.; Arradondo, J.; Li, T.; Yong, K.; He, S. A biocatalytic/reductive etherification approach to substitued piperidinyl ethers Tetrahedron 2014, 70, 4563-4570
28. For a description of the protocols for enzyme inhibition assays, see: Liu, J.; Gorski, J. N.; Gold, S. J.; Chen, D.; Chen, S.; Forrest, G.; Itoh, Y.; Marsh, D. J.; McLaren, D. G.; Shen, Z.; Sonatore, L.; Carballo-Jane, E.; Craw, S.; Guan, X.; Karanam, B.; Sakaki, J.; Szeto, D.; Tong, X.; Xiao, J.; Yoshimoto, R.; Yu, H.; Roddy, T. P.; Balkovec, J.; Pinto, S. Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight and modulates gut peptide release: potential insight into mechanism of action Obesity 2013, 21, 1406-1415
29. Inhibition of ACAT has been shown to cause adverse changes in preclinical species, see: Floettmann, J. E.; Buckett, L. K.; Turnbull, A. V.; Smith, T.; Hallberg, C.; Birch, A.; Lees, D.; Jones, H. B. ACAT-selective and nonselective DGAT1 inhibition: adrenocortical effects. A cross-species comparison Toxicol. Pathol. 2013, 41, 941-950
30. Radiolabeled MK-499 has been used in a hERG (potassium ion channel Kv11.1) binding assay to provide an initial screen of a compounds potential to interact with hERG. Blocking hERG can result in QTc prolongation, a serious adverse effect. Raab, C. E.; Butcher, J. W.; Connolly, T. M.; Karczewski, J.; Yu, N. X.; Staskiewicz, S. J.; Liverton, N.; Dean, D. C.; Melillo, D. G. Synthesis of the first sulfur-35-labeled hERG radioligand Bioorg. Med. Chem. Lett. 2006, 16, 1692-1695
31. The positive control, Cpd A, was originally disclosed by scientists at Japan Tobacco and Tularik: Fox, B. M.; Furukawa, N. H.; Hao, X.; Lio, K.; Inaba, T.; Jackson, S. M.; Kayser, F.; Labelle, M.; Kexue, M.; Matsui, T.; McMinn, D. L.; Ogawa, N.; Rubenstein, S. M.; Sagawa, S.; Sugimoto, K.; Suzuki, M.; Tanaka, M.; Ye, G.; Yoshida, A.; Zhang, J. A. Preparation of fused bicyclic nitrogen-containing heterocycles, useful in the treatment or prevention of metabolic and cell proliferative diseases. WO 2004/ 047755A2. CAN 14138623.
32. Mercangöz, A.; Korkmaz, F. Mutagenicity of 1-ethyl-2,4,5-triphenyl-1H-imidazole and six derivatives in Salmonella typhimurium Gazi Univ. J. Sci. 2012, 25, 1-8
33. For an excellent discussion on in silico prediction of mutagenicity, see: Hillebrecht, A.; Muster, W.; Brigo, A.; Kansy, M.; Weiser, T.; Singer, T. Comparative evaluation of in silico systems for Ames test mutagenicity prediction: Scope and limitations Chem. Res. Toxicol. 2011, 24, 843-854
34. Guidance for Industry: safety testing of drug metabolites. Center for Drug Evaluation and Research, U.S. FDA, February, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf (downloaded January 2014).